The need for new, more effective, and less toxic antifungal antibiotics for the treatment of disseminated mycotic infections is obvious in light of the significant toxicities and failure rates of the currently available systemic antifungal agents. This problem has become particularly relevant in view of the fact that opportunistic disseminated mycoses are a common complication of acquired immunodeficiency syndrome. Discovery of new antibiotics has relied primarily upon isolation of such agents from natural sources. The major advantage of this approach over chemical synthesis or modification of existing agents is the probability of identifying new prototype drugs with quite different chemical structures and, hence, dissimilar toxicities and cross-resistances with present drug therapies. Although microorganisms have traditionally served as the primary source for new antibiotics, it has recently been shown that higher plants also serve as sources for a number of diverse antimicrobial agents (2) (3) (4) (5) (6) (7) (8) .
We previously reported the isolation of an antifungal alkaloid, eupolauridine (compound II), from the ethanolic extract of the root bark of Cleistopholis patens (Benth) Engl. and Diels (Annonaceae) collected in Nigeria (6) . Reexamination of the ethanolic extract of the same plant has resulted in the isolation of a new alkaloid, 3-methoxysampangine (compound I), in addition to the known alkaloids eupolauridine (compound II), liriodenine (compound III), and eupolauridine N-oxide (compound IV) (Fig. 1 Table 1 .
Qualitative antifungal evaluation. In vitro evaluation of activity versus Candida albicans NIH B311, Cryptococcus neoformans ATCC 32264, and Aspergillusfumigatus ATCC 26934 was accomplished by using the agar-well difusion assay previously described (2) , with the following modifications. C. albicans NIH B311, which is used to induce experimental disseminated candidiasis, was used for the initial qualitative evaluation of anticandidal activity. The organism was grown in Sabouraud dextrose broth for 24 h at 37°C, after which the cells were harvested by centrifugation (4°C, 2,000 rpm, 3 min). After centrifugation, the cells were washed and suspended in sterile 0.9% saline to give a final concentration of 106 CFU/ml (adjusted with a hemacytometer). Inocula of C. neoformans and A. fumigatus were prepared by suspension of the surface growth of stock agar slants in sterile H20 as previously described (2, 5) . Culture plates (15 by 100 mm) for the qualitative assay were prepared from 25 ml of Sabouraud dextrose agar. With sterile cotton swabs, the plates were streaked with the suspension of the appropriate test organism. Cylindrical plugs were removed from the agar plates with a sterile cork borer to produce wells with diameters of approximately 11 mm. To the wells was added 100 RI of a solution or suspension of an extract, fraction, or pure compound. Crude extracts and fractions were tested at a concentration of 20 mg/ml, whereas pure compounds were tested at 1 mg/ml. When solvents other than H20, EtOH, MeOH, dimethyl sulfoxide, dimethyl formamide, or acetone were required to dissolve extracts or compounds, solvent blanks were included. Antifungal activity was recorded as the width (in millimeters) of the zone of inhibition, measured from the edge of the agar well to the edge of the zone, following incubation of the plates for 24 h (37°C for C. albicans, 30°C for A. flavus and 26°C for C. neoformans). The antifungal agents amphotericin B and ketoconazole were included as positive controls in each assay.
Quantitative antifungal evaluation. The method used to determine the MIC was the twofold serial broth dilution assay (2, 5, 6) in yeast nitrogen broth (Difco Laboratories) for C. albicans and C. neoformans and Sabouraud dextrose broth for A. fumigatus. The inoculum for the MIC determination was prepared as described for the qualitative evaluation. With a calibrated sterile wire loop, each tube was inoculated with 10 ,ul of the suspension. The MIC was taken as the lowest concentration of a compound that inhibited the growth of the test organisms after an appropriate incubation period (37°C for 24 and 48 h for C. albicans; 30°C for 48 and 72 h for A. fumigatus; 26°C for 48 and 72 h for C. neoformans). The antifungal agent amphotericin B was included as a positive control in each assay.
RESULTS AND DISCUSSION
As part of our continuing search for new anticandidal drugs from natural sources, we recently reported the isolation of the antifungal alkaloid eupolauridine (compound II) from the root bark of the West African tree C. patens. Further examination of the active ethanolic extract of the root bark by a bioassay-directed fractionation approach resulted in the isolation and identification of a novel antifungal alkaloid, 3-methoxysampangine (compound I). The dried, ground root bark of C. patens was percolated with n-hexane, followed by 95% EtOH and then hot EtOH. The antifungal activity was concentrated in the ethanolic extracts, which were combined and subjected to bioassaydirected fractionation by partitioning between CHC13 and H20 and then EtOAc and H20. The active CHCl3-and EtOAc-soluble fractions were combined, and the combined organic fraction was chromatographed over silica gel by using CHCl3 and gradually increasing percentages of MeOH in CHC13 as eluents. Fractions were pooled on the basis of similar TLC patterns, and activity was found to be concentrated in fractions eluted with 5% MeOH-CHCl3, which were pooled and further purified by chromatography over neutral alumina by using mixtures of EtOAc-n-hexane as eluting solvents. Four pooled fractions were each further purified by chromatography over silica gel by using EtOAcMeOH as the eluting solvent to yield eupolauridine (compound II), 3-methoxysampangine (compound I), eupolauridine N-oxide (compound IV), and liriodenine (compound III), respectively.
Eupolauridine (compound II) and liriodenine (compound III) were identified by direct comparisons (melting point, mixture melting point, TLC, and MS) with authentic samples of eupolauridine and liriodenine obtained previously in our laboratory (4, 6) . The was based on a comparison of its physicochemical and spectral properties ('H and 13C NMR and MS) with the data reported for compound IV (10) .
The new compound, 3-methoxysampangine (compound I) was isolated in a 0.00016% yield from the root bark as yellow needles (melting point, 213 to 215°C). Electron-impact MS showed a molecular ion peak at mlz 262, corresponding to the molecular formula C16H,oN202. This formula was confirmed by high-resolution MS and indicated the presence of a condensed-ring system (4) . This was verified by the UV spectrum, which showed bands at Xmax 309, 332, and 429 nm, characteristic of a highly conjugated oxoalkaloid, and the infrared spectrum, which showed a carbonyl absorption band at 1,673 cm-'. The 300-MHz 'H NMR spectrum ( Table 1. 3-Methoxysampangine demonstrated significant in vitro activity against the yeasts C. albicans and C. neoformans and the filamentous fungus A. fumigatus. The MIC of compound I were 3.12 ,ug/ml for C. albicans and A. fumigatus and 0.2 pug/ml for C. neoformans. By comparison, the MICs of amphotericin B range from 0.78 ,ug/ml for C. albicans to 3.12 ,ug/ml for C. neoformans and 1.56 pLg/ml for A. fumigatus. Additional studies on antifungal activity are in progress. The antifungal activities of liriodenine (compound III) and the eupolauridine (compound II) have been described previously (4, 6) ; however, eupolauridine N-oxide showed no antifungal activity.
